Our Focus

LEADER IN PSILOCYBIN-BASED TREATMENTS TARGETING OBESITY

NeonMind is developing the first and only novel psilocybin-based drug candidates targeting obesity. NeonMind’s lead candidate, NEO-001, aims to produce neuropharmacological changes induced by psilocybin, in conjunction with psychotherapy, to achieve durable weight loss for patients suffering from obesity. NeonMind has an additional pipeline opportunity, NEO-002, which employs low-dose psilocybin to control appetite.

LAUNCHING NEONMIND-BRANDED SPECIALTY MENTAL HEALTH CLINICS

Established world-class Specialty Clinics Advisory Board with the appointment of Dr. Sagar Parikh, MD, as Chairman to become a trusted partner in interventional psychiatry through NeonMind-branded clinics.

Expanding pipeline of innovative treatments such as ketamine therapy and neurostimluation have the potential to revolutionize psychiatry and address a growing mental illness market. The World Health Organization estimates that mental health disorders affect nearly 700 million people globally. 

Currently, NeonMind sees an opportunity to provide integrated mental health services and deliver evidence-backed, innovative treatments tailored to local market needs. 

The Company expects to launch its 1st location by the end of 2021. 

NEONMIND’S THERAPEUTIC PIPELINE ADDRESSES A BILLION-DOLLAR PER YEAR GLOBAL WEIGHT MANAGEMENT MARKET

Obesity is the cause behind many diseases and other health problems and has been formally recognized by the World Health Organization as a global epidemic with an estimated global annual spend of $245 billion by 2022. 

2.8 million people die each year as a result of being overweight or obese; and

In 2016, more than 1.9 billion adults, 18 years and older, were overweight.

EVIDENCE-BACKED APPROACH

NeonMind demonstrated that psilocybin reduced weight gain by 31% and 28% for low and high dose, respectively, in preclinical studies. 

The Company has filed 11 US provisional and 4 PCT applications covering a spectrum of weight management conditions. 

NeonMind expects to have the first patient enrolled in what will be the world’s first psychedelic proof-of-concept study in obese patients in the first half of 2022.